HJ-4-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors • ScreeningLibraries • Proteinswww.MedChemEHJ-4Cat.No.:HY-178921CASNo.:1313741-00-2分子式:C₂₃H₂₄N₂O₄分子量:392.45作用靶点:DrugDerivative;Apoptosis作用通路:Others;Apoptosis储存方式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY生物活性HJ-4是Piperine(HY-N0144)的衍生物。HJ-4通过剂量依赖性地减少集落形成和DNA合成，强效抑制结直肠癌(CRC)细胞的增殖。HJ-4显著抑制CRC细胞的粘附、迁移、侵袭并诱导凋亡(apoptosis)。HJ-4在植入HCT116/SW480肿瘤球的鸡胚绒毛膜尿囊膜(CAM)模型中显示出抗肿瘤效能。HJ-4可用于结直肠癌(CRC)研究[1]。体外研究HJ-4(3.125-100μM,24h)inhibitsviabilityofCRCcells(HCT116:IC50=15.82μM;SW480:IC50=20.46μM)[1].HJ-4(8-32μM,48h)reducescolonynumberandsizeofHCT116/SW480cells[1].HJ-4(8-32μM,24h)decreasesEdU-positiveHCT116/SW480cellsinEdUincorporationassay,dose-dependentlyinhibitingDNAsynthesis[1].HJ-4(8-32μM,0-48h)inhibitsadhesion,migration,andinvasionofHCT116/SW480cells[1].HJ-4(8-32μM,24h)upregulatesp53,PUMA,BAX,cleavedcaspase-3,cleavedPARP,anddownregulatesBCL-2,β-catenin,CyclinD1inHCT116/SW480cells[1].HJ-4(8-32μM,24h)increasesp53/BAXexpressioninHCT116/SW480cells,andpromotesYO-PRO-1(earlyapoptosis)andPI(lateapoptosis)positivecellsinHCT116cellsviaYO-PRO-1/PIstaining[1].WesternBlotAnalysis[1]CellLine:HCT116/SW480cellsConcentration:8,16,32μMIncubationTime:24h1/2 MasterofBioactiveMolecules—您身边的抑制剂大师www.MedChemEResult:Upregulatedp53,PUMA,BAX,cleavedcaspase-3,cleavedPARP.DownregulatedBCL-2,β-catenin,CyclinD1.体内研究HJ-4(8-32μM,localapplicationtotumorsite,oncedailyfor7days)inhibitsangiogenesisinchickenembryochorioallantoicmembrane(CAM)modelimplantedwithHCT116/SW480tumorspheroids[1].AnimalModel:HCT116/SW480coloncancercell-derivedspheroidswereimplantedintothevascular-richregionsofthechorioallantoicmembrane(CAM)of7-day-oldfertilizedchickenembryos[1]Dosage:8,16,32μMAdministration:localapplicationtotumorsite,oncedailyfor7daysResult:Reducedtumorweight.Showedpotentanti-angiogeniceffectsintheCAMmodel.Decreasedthenumberoftertiarybloodvessels.DidnotcauseobviousembryonictoxicityintheCAMmodel.REFERENCESZhangL,etal.HJ-4,anovelpiperinederivative,inhibitstumorgrowthandangiogenesisviap53activationandoncogenicpathwayinhibitionincolorectalcancermodels.SciRep.2025Sep29;15(1):33541.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forres